Stocktoria
Esperion Therapeutics, Inc. ESPR
Esperion Therapeutics, Inc. (ESPR) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $403.1M at a -5.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.347 |
| Retained earnings / assets | -3.485 |
| EBIT / assets | 0.129 |
| Equity / liabilities | -0.393 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics, Inc. | 3/9 | -8.63 | — | +21.3% |
| ARDX | ARDELYX, INC. | 2/9 | -2.34 | — | +22.1% |
| INVA | Innoviva, Inc. | 3/9 | 6.59 | — | +14.7% |
| SVA | SINOVAC BIOTECH LTD | 3/9 | 8.06 | — | +6.8% |
| ARQT | Arcutis Biotherapeutics, Inc. | 4/9 | -3.68 | — | +91.3% |
| MNKD | MANNKIND CORP | 3/9 | -11.89 | 218.2 | +22.2% |
| ZLAB | Zai Lab Ltd | 3/9 | -3.61 | — | +15.3% |
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
FAQ
Is ESPR financially healthy?
Esperion Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ESPR pay a dividend?
No, Esperion Therapeutics, Inc. does not currently pay a dividend.
How profitable is ESPR?
In FY2025, Esperion Therapeutics, Inc. had a net margin of -5.6%.
What is the analyst price target for ESPR?
The average Wall-Street price target for Esperion Therapeutics, Inc. is $3.19, from 4 analysts.
Is ESPR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Esperion Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.